StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3037% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

Arrowhead Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Arrowhead Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $723.37M, up 27.3% year over year. For fiscal 2025 it was $607.16M, up 20.0% from the year before. Over ten years it grew 29.1% a year on average. The highest annual figure on record is $607.16M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Sep 30, 2025$607.16M+20.0%
FY2024Sep 30, 2024$505.87M+43.2%
FY2023Sep 30, 2023$353.19M+18.8%
FY2022Sep 30, 2022$297.31M+44.1%
FY2021Sep 30, 2021$206.34M+60.1%
FY2020Sep 30, 2020$128.88M+59.0%
FY2019Sep 30, 2019$81.05M+53.0%
FY2018Sep 30, 2018$52.97M+4.1%
FY2017Sep 30, 2017$50.90M-18.1%
FY2016Sep 30, 2016$62.12M+31.4%
FY2015Sep 30, 2015$47.27M+104.3%
FY2014Sep 30, 2014$23.14M+165.8%
FY2013Sep 30, 2013$8.71M+61.5%
FY2012Sep 30, 2012$5.39M+64.5%
FY2011Sep 30, 2011$3.28M+518.9%
FY2010Sep 30, 2010$529.60K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$198.22M+22.1%
Q2 FY2026CQ1 2026Mar 31, 2026$173.25M+30.2%
Q1 FY2026CQ4 2025Dec 31, 2025$177.20M+29.3%
Q4 FY2025CQ3 2025Sep 30, 2025$174.69M+28.6%
Q3 FY2025CQ2 2025Jun 30, 2025$162.37M+6.5%
Q2 FY2025CQ1 2025Mar 31, 2025$133.10M+31.6%
Q1 FY2025CQ4 2024Dec 31, 2024$137.00M+17.6%
Q4 FY2024CQ3 2024Sep 30, 2024$135.83M+36.0%
Q3 FY2024CQ2 2024Jun 30, 2024$152.43M+60.9%
Q2 FY2024CQ1 2024Mar 31, 2024$101.12M+35.0%
Q1 FY2024CQ4 2023Dec 31, 2023$116.49M+39.2%
Q4 FY2023CQ3 2023Sep 30, 2023$99.86M+19.8%
Q3 FY2023CQ2 2023Jun 30, 2023$94.76M+31.3%
Q2 FY2023CQ1 2023Mar 31, 2023$74.88M-1.5%
Q1 FY2023CQ4 2022Dec 31, 2022$83.70M+27.3%
Q4 FY2022CQ3 2022Sep 30, 2022$83.38M+26.8%
Q3 FY2022CQ2 2022Jun 30, 2022$72.18M+21.7%
Q2 FY2022CQ1 2022Mar 31, 2022$75.99M+70.0%
Q1 FY2022CQ4 2021Dec 31, 2021$65.77M+79.9%
Q4 FY2021CQ3 2021Sep 30, 2021$65.77M+51.2%
Q3 FY2021CQ2 2021Jun 30, 2021$59.33M+82.1%
Q2 FY2021CQ1 2021Mar 31, 2021$44.70M+51.8%
Q1 FY2021CQ4 2020Dec 31, 2020$36.56M+56.4%
Q4 FY2020CQ3 2020Sep 30, 2020$43.49M+85.9%
Q3 FY2020CQ2 2020Jun 30, 2020$32.57M+68.8%
Q2 FY2020CQ1 2020Mar 31, 2020$29.44M+41.6%
Q1 FY2020CQ4 2019Dec 31, 2019$23.37M+33.0%
Q4 FY2019CQ3 2019Sep 30, 2019$23.39M+46.2%
Q3 FY2019CQ2 2019Jun 30, 2019$19.29M+60.1%
Q2 FY2019CQ1 2019Mar 31, 2019$20.80M+73.3%
Q1 FY2019CQ4 2018Dec 31, 2018$17.57M+36.0%
Q4 FY2018CQ3 2018Sep 30, 2018$15.99M+18.1%
Q3 FY2018CQ2 2018Jun 30, 2018$12.05M+8.2%
Q2 FY2018CQ1 2018Mar 31, 2018$12.00M+4.9%
Q1 FY2018CQ4 2017Dec 31, 2017$12.92M+35.6%
Q4 FY2017CQ3 2017Sep 30, 2017$13.54M-58.1%
Q3 FY2017CQ2 2017Jun 30, 2017$11.14M–
Q2 FY2017CQ1 2017Mar 31, 2017$11.44M–
Q1 FY2017CQ4 2016Dec 31, 2016$9.53M–
Q4 FY2016CQ3 2016Sep 30, 2016$32.33M–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?